002317 众生药业
已收盘 08-14 15:00:00
资讯
新帖
简况
众生药业:RAY1225注射液III期临床试验已完成全部参与者入组
证券之星 · 08-12
众生药业:RAY1225注射液III期临床试验已完成全部参与者入组
众生药业:乐睿灵®已形成医疗机构终端+线上平台的核心销售渠道体系
证券之星 · 08-12
众生药业:乐睿灵®已形成医疗机构终端+线上平台的核心销售渠道体系
众生药业:中国民营药企穿越周期最朴素的样子
蓝鲸财经 · 08-11
众生药业:中国民营药企穿越周期最朴素的样子
股市必读:众生药业新发布《关于全资子公司获得布瑞哌唑化学原料药上市申请批准通知书的公告》
证券之星 · 08-03
股市必读:众生药业新发布《关于全资子公司获得布瑞哌唑化学原料药上市申请批准通知书的公告》
众生药业(002317.SZ):原料药布瑞哌唑获得化学原料药上市申请批准
智通财经 · 07-31
众生药业(002317.SZ):原料药布瑞哌唑获得化学原料药上市申请批准
公司问答丨众生药业:已递交昂拉地韦片青少年单纯性甲型流感适应症的补充申请 目前正在审评审批进程中
格隆汇 · 07-30
公司问答丨众生药业:已递交昂拉地韦片青少年单纯性甲型流感适应症的补充申请 目前正在审评审批进程中
众生药业(002317)披露使用闲置自有资金进行委托理财的进展公告,7月28日股价下跌5.26%
证券之星 · 07-28
众生药业(002317)披露使用闲置自有资金进行委托理财的进展公告,7月28日股价下跌5.26%
众生药业新提交“晶逸宁”、“未公开”等3件商标注册申请
证券之星 · 07-25
众生药业新提交“晶逸宁”、“未公开”等3件商标注册申请
众生药业:已递交昂拉地韦片青少年单纯性甲型流感适应症的补充申请
证券之星 · 07-23
众生药业:已递交昂拉地韦片青少年单纯性甲型流感适应症的补充申请
研报掘金丨华源证券:首予众生药业“买入”评级,进入创新药价值兑现关键阶段
格隆汇 · 07-22
研报掘金丨华源证券:首予众生药业“买入”评级,进入创新药价值兑现关键阶段
众生药业最新公告:控股子公司获得日本专利证书
证券之星 · 07-20
众生药业最新公告:控股子公司获得日本专利证书
7月20日众生药业跌5.08%,红土创新医疗保健股票A基金重仓该股
证券之星 · 07-20
7月20日众生药业跌5.08%,红土创新医疗保健股票A基金重仓该股
SpaceX据称向鸿海下达巨额订单 订购价值520亿美元AI服务器机架
格隆汇 · 07-20
SpaceX据称向鸿海下达巨额订单 订购价值520亿美元AI服务器机架
众生药业:先强药业致力于以优质的CDMO服务和核心技术产品成为特色原料药的价值创造者
证券之星 · 07-20
众生药业:先强药业致力于以优质的CDMO服务和核心技术产品成为特色原料药的价值创造者
7月17日众生药业跌5.44%,红土创新医疗保健股票A基金重仓该股
证券之星 · 07-17
7月17日众生药业跌5.44%,红土创新医疗保健股票A基金重仓该股
众生药业(002317)披露2024年员工持股计划锁定期届满暨解锁条件成就公告,7月16日股价下跌10.0%
证券之星 · 07-16
众生药业(002317)披露2024年员工持股计划锁定期届满暨解锁条件成就公告,7月16日股价下跌10.0%
7月16日众生药业(002317)龙虎榜数据:机构净卖出5211.89万元,北向资金净买入5098.97万元
证券之星 · 07-16
7月16日众生药业(002317)龙虎榜数据:机构净卖出5211.89万元,北向资金净买入5098.97万元
7月16日众生药业跌10.00%,红土创新医疗保健股票A基金重仓该股
证券之星 · 07-16
7月16日众生药业跌10.00%,红土创新医疗保健股票A基金重仓该股
股市必读:众生药业(002317)7月15日董秘有最新回复
证券之星 · 07-16
股市必读:众生药业(002317)7月15日董秘有最新回复
半年BD狂飙千亿、龙头预增13倍!创新药涨停潮再起
格隆汇 · 07-15
半年BD狂飙千亿、龙头预增13倍!创新药涨停潮再起
暂无数据
公司概况
公司名称:
广东众生药业股份有限公司
所属行业:
医药制造业
上市日期:
2009-12-11
主营业务:
广东众生药业股份有限公司的主营业务是药品研发、生产和销售。公司的主要产品是昂拉地韦片、来瑞特韦片、复方血栓通系列产品、脑栓通胶囊、复方丹参片、众生丸系列产品、清热祛湿颗粒、羧甲司坦口服溶液(片)、盐酸氨溴索口服溶液、头孢克肟分散片、头孢拉定胶囊、异烟肼片、吡嗪酰胺片、盐酸乙胺丁醇片、利福平胶囊、利巴韦林片、硫糖铝口服混悬液、瑞巴派特片、奥美拉唑肠溶胶囊、盐酸氮䓬斯汀滴眼液、普拉洛芬滴眼液、地夸磷索钠滴眼液、环孢素滴眼液(III)、氯雷他定片、富马酸氯马斯汀口服溶液。
发行价格:
55.00
{"stockData":{"symbol":"002317","market":"SZ","secType":"STK","nameCN":"众生药业","latestPrice":27.45,"timestamp":1786691022000,"preClose":29,"halted":0,"volume":55051861,"delay":0,"changeRate":-0.0534,"floatShares":762000000,"shares":850000000,"eps":0.3447,"marketStatus":"已收盘","change":-1.55,"latestTime":"08-14 15:00:00","open":28.49,"high":28.9,"low":27.1,"amount":1530000000,"amplitude":0.0621,"askPrice":27.46,"askSize":213,"bidPrice":27.45,"bidSize":1162,"shortable":0,"etf":0,"ttmEps":0.3447,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1786930200000},"marketStatusCode":5,"adr":0,"adjPreClose":29,"symbolType":"stock","openAndCloseTimeList":[[1786671000000,1786678200000],[1786683600000,1786690800000]],"highLimit":31.9,"lowLimit":26.1,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":849930477,"isCdr":false,"pbRate":5.92,"roa":"--","peRate":79.634465,"roe":"2.43%","epsLYR":0.33,"committee":-0.115823,"marketValue":23331000000,"turnoverRate":0.0723,"status":1,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2026-08-17。","floatMarketCap":20906000000},"requestUrl":"/m/hq/s/002317/tweets","defaultTab":"tweets","newsList":[{"id":"2658928252","title":"众生药业:RAY1225注射液III期临床试验已完成全部参与者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2658928252","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658928252?lang=zh_cn&edition=full","pubTime":"2026-08-12 11:37","pubTimestamp":1786505826,"startTime":"0","endTime":"0","summary":"RAY1225注射液用于治疗中国肥胖/超重患者的安全性和有效性的III期临床试验,RAY1225注射液单药治疗2型糖尿病患者的安全性和有效性、安慰剂对照的III期临床试验和RAY1225注射液与口服降糖药物联合治疗2型糖尿病患者的安全性和有效性、司美格鲁肽注射液对照的III期临床试验均已顺利完成全部参与者入组工作,目前正在积极推进III期临床试验。基于“安全至上、循序渐进”的原则,RAY1225注射液III期临床试验沿用低剂量起始缓和爬坡的试验方案设计。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081200016270.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002317","BK0077","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658692844","title":"众生药业:乐睿灵®已形成医疗机构终端+线上平台的核心销售渠道体系","url":"https://stock-news.laohu8.com/highlight/detail?id=2658692844","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658692844?lang=zh_cn&edition=full","pubTime":"2026-08-12 11:37","pubTimestamp":1786505822,"startTime":"0","endTime":"0","summary":"证券之星消息,众生药业08月12日在投资者关系平台上答复投资者关心的问题。乐睿灵已形成医疗机构终端+线上平台的核心销售渠道体系。此外,乐睿灵已获得常规批准,公司目前正稳步推进乐睿灵向基层医疗机构、零售药店的拓展落地,逐步完善从等级医院到基层医疗机构、零售药店的全域渠道布局,全方位提升药品可及性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081200016265.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0077","BK0239","002317"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658952961","title":"众生药业:中国民营药企穿越周期最朴素的样子","url":"https://stock-news.laohu8.com/highlight/detail?id=2658952961","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658952961?lang=zh_cn&edition=full","pubTime":"2026-08-11 12:44","pubTimestamp":1786423460,"startTime":"0","endTime":"0","summary":"众生药业是个例外。拆开这套操作,能看见一家中国药企穿越周期的方法论。众生药业从2010年就开启了创新转型之路,目标是让一家传统中药企业长出创新药的筋骨。众生药业决定锚定PB2靶点全力攻坚。2018年10月,众生药业设立控股子公司众生睿创,聚焦创新药物研发与商业化。复方血栓通胶囊在国内眼科内服中成药市场市占率长期稳居第一。众生药业的应对方式没有太多花活。05 成果兑现三重考验之后,众生药业交出的答卷在数据上有了回响。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1786331694308753150","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK0239","002317","BK0077","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656486693","title":"股市必读:众生药业新发布《关于全资子公司获得布瑞哌唑化学原料药上市申请批准通知书的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2656486693","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656486693?lang=zh_cn&edition=full","pubTime":"2026-08-03 01:00","pubTimestamp":1785690046,"startTime":"0","endTime":"0","summary":"公司公告汇总:全资子公司获布瑞哌唑化学原料药上市申请批准通知书,登记号Y20250000228,审批结论为符合药品注册有关要求,批准注册。布瑞哌唑制剂用于治疗成人精神分裂症,2025年及2026年一季度销售额分别为878万元、1,001万元。该事项丰富公司特色原料药产品管线,有利于拓展研发及销售,但不会对公司当期经营业绩产生重大影响。药品销售受政策、市场环境等因素影响,存在不确定性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080300000388.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0077","002317"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655354395","title":"众生药业(002317.SZ):原料药布瑞哌唑获得化学原料药上市申请批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2655354395","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655354395?lang=zh_cn&edition=full","pubTime":"2026-07-31 17:28","pubTimestamp":1785490080,"startTime":"0","endTime":"0","summary":"智通财经APP讯,众生药业(002317.SZ)发布公告,公司全资子公司广东先强药业有限公司于近日收到国家药品监督管理局核准签发的原料药布瑞哌唑《化学原料药上市申请批准通知书》。布瑞哌唑制剂用于治疗成人精神分裂症。本次原料药布瑞哌唑获得《化学原料药上市申请批准通知书》,表明该原料药已符合国家相关药品审评技术标准,已批准可在国内制剂中使用和销售,将丰富公司特色原料药产品管线,有利于公司拓展该品种的研发及销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1474665.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","BK0077","BK0188","BK0239","002317"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655255448","title":"公司问答丨众生药业:已递交昂拉地韦片青少年单纯性甲型流感适应症的补充申请 目前正在审评审批进程中","url":"https://stock-news.laohu8.com/highlight/detail?id=2655255448","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655255448?lang=zh_cn&edition=full","pubTime":"2026-07-30 14:55","pubTimestamp":1785394545,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0188","002317","BK0077","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654889288","title":"众生药业(002317)披露使用闲置自有资金进行委托理财的进展公告,7月28日股价下跌5.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2654889288","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654889288?lang=zh_cn&edition=full","pubTime":"2026-07-28 22:13","pubTimestamp":1785247995,"startTime":"0","endTime":"0","summary":"截至2026年7月28日收盘,众生药业报收于26.49元,较前一交易日下跌5.26%,最新总市值为225.15亿元。近日,众生药业发布《关于使用闲置自有资金进行委托理财的进展公告》。公告显示,公司于2026年7月27日和28日,通过控股子公司众生睿创分别使用3,500万元和3,000万元闲置自有资金购买东莞银行和中信银行的保本浮动收益型结构性存款产品,产品期限分别为92天和79天,起息日均为2026年7月29日,预期年化收益率分别为1.10%至1.75%和1.00%至1.72%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072800039681.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0077","BK0188","002317"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654324058","title":"众生药业新提交“晶逸宁”、“未公开”等3件商标注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2654324058","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654324058?lang=zh_cn&edition=full","pubTime":"2026-07-25 07:15","pubTimestamp":1784934922,"startTime":"0","endTime":"0","summary":"证券之星消息,根据天眼查APP数据显示,近日广东众生药业股份有限公司新提交“晶逸宁”、“未公开”等3件商标注册申请。商标申请详情如下:今年以来广东众生药业股份有限公司新申请注册商标29件,截止目前公司共持有注册商标184件,另有33件商标尚在注册申请中。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072500005429.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","BK0077","002317"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653922647","title":"众生药业:已递交昂拉地韦片青少年单纯性甲型流感适应症的补充申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2653922647","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653922647?lang=zh_cn&edition=full","pubTime":"2026-07-23 08:45","pubTimestamp":1784767509,"startTime":"0","endTime":"0","summary":"证券之星消息,众生药业07月22日在投资者关系平台上答复投资者关心的问题。公司将及时依据信息披露规则履行信息披露责任。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072300010820.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0077","002317","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653747734","title":"研报掘金丨华源证券:首予众生药业“买入”评级,进入创新药价值兑现关键阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2653747734","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653747734?lang=zh_cn&edition=full","pubTime":"2026-07-22 14:34","pubTimestamp":1784702084,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["161027","BK0239","BK0188","159992","002317","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652219296","title":"众生药业最新公告:控股子公司获得日本专利证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2652219296","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652219296?lang=zh_cn&edition=full","pubTime":"2026-07-20 22:01","pubTimestamp":1784556089,"startTime":"0","endTime":"0","summary":"众生药业(002317.SZ)公告称,公司控股子公司广东众生睿创生物科技有限公司收到日本特许厅颁发的专利证书。该专利为在研创新结构多肽药物RAY1225注射液的核心专利,具有GLP-1和GIP受体双重激动活性。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072000039118.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002317","BK0239","BK0188","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652407296","title":"7月20日众生药业跌5.08%,红土创新医疗保健股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652407296","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652407296?lang=zh_cn&edition=full","pubTime":"2026-07-20 16:39","pubTimestamp":1784536789,"startTime":"0","endTime":"0","summary":"证券之星消息,7月20日众生药业跌5.08%,收盘报26.89元,换手率13.73%,成交量104.59万手,成交额28.82亿元。根据2026基金半年报公募基金重仓股数据,重仓该股的公募基金共1家,其中持有数量最多的公募基金为红土创新基金的红土创新医疗保健股票A。红土创新医疗保健股票A的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072000024917.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002317","BK0077","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652261241","title":"SpaceX据称向鸿海下达巨额订单 订购价值520亿美元AI服务器机架","url":"https://stock-news.laohu8.com/highlight/detail?id=2652261241","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652261241?lang=zh_cn&edition=full","pubTime":"2026-07-20 11:58","pubTimestamp":1784519908,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["SOXX","LU2097344431.USD","LU1868836591.USD","SG9999000418.SGD","LU1642822529.SGD","LU2394011477.USD","IE00B3M56506.USD","LU2108987350.USD","LU1551013342.USD","LU1712237335.SGD","LU2089283258.USD","LU2491049909.HKD","LU0048584097.USD","IE00BK4W5L77.USD","LU1923622614.USD","USD","LU2023250330.USD","BK4592","LU1934455194.USD","LU2125909247.SGD","LU0661504455.SGD","LU0642271901.SGD","IE0034235188.USD","LU2237443549.SGD","LU0187121727.USD","LU0323591593.USD","LU2999663052.SGD","LU0158827948.USD","LU0345769631.USD","LU0011850046.USD","SG9999015341.SGD","LU0061474960.USD","LU1720051017.SGD","IE00BZ199S13.USD","LU2272731865.HKD","LU2294711713.HKD","LU0133085943.USD","XLK","SGXZ31699556.SGD","IE00BHPRN162.USD","LU2462591350.SGD","LU0353189763.USD","GB00BDT5M118.USD","LU0345768740.USD","BK4532","LU1037948541.HKD","LU1267930490.SGD","LU0353189680.USD","LU0265550946.USD","LU0466842654.USD","LU0788109477.HKD","BK4141","LU1003077747.HKD","LU1880398471.USD","LU2430703178.SGD","LU0006306889.USD","NVDA","LU2461242641.AUD","LU0256863811.USD","07388","IE00B3S45H60.SGD","IE0004445015.USD","LU1261432733.SGD","LU0557290698.USD","LU2506951792.HKD","SG9999015978.USD","LU0417517546.SGD","LU0820561909.HKD","LU1992135472.HKD","SG9999015358.SGD","LU2746668974.SGD","LU0683600562.USD","LU1951198990.SGD","USXF","LU1035775433.USD","LU0079474960.USD","LU2065171402.SGD","LU2077746001.SGD","LU1914381329.SGD","LU2552382132.HKD","SG9999015945.SGD","NVDX","IE00BJTD4V19.USD","LU1674673428.USD","LU1119994496.HKD","LU0347712357.USD","07788","LU2092627202.USD","LU1691799644.USD","LU0689626769.HKD","LU1280957306.USD","LU2552382058.USD","LU1242518857.USD","BK4551","LU2750360997.AUD","BK4549","LU2360107168.USD","LU1868836914.USD","LU0342679015.USD","IE00BFSS7M15.SGD","IE00BMPRXQ63.HKD","LU0528227936.USD","LU2237443895.HKD","LU1868837300.USD","LU0251132253.USD","EFIV","IE00B775SV38.USD","LU1069347547.HKD","BK4608","LU2456880835.USD","LU0157215616.USD","BK4548","IE00B19Z9505.USD","LU0211328371.USD","LU1803068979.SGD","LU0072462426.USD","LU2420271590.USD","LU2191332357.HKD","LU0979878070.USD","LU2357305700.SGD","LU1153585028.USD","NULC","LU2272731782.SGD","LU2133065610.SGD","IE000Q6AESB8.SGD","LU2322448791.USD","BK4554","LU2106854487.HKD","IE00BQXX3D17.EUR","LU0053666078.USD","LU0672654240.SGD","LU0198837287.USD","LU0276348264.USD","LU2111349929.HKD","NVD3.UK","LU1244550577.SGD","LU1989764664.SGD","LU2471134796.USD","IE0034235303.USD","LU2360032135.SGD","LU2471134879.HKD","IE00BJLML261.HKD","LU2543165471.USD","LU1232071149.USD","LU2403377893.USD","BK4614","IE00B4YYXB79.USD","SG9999014914.USD","LU0942090050.USD","WISE","LU0289961442.SGD","ROM","BK4587","LU0266013472.USD","LU1880398554.USD","LU0310799852.SGD","LU1571399168.USD","TYLG","LU1934455863.HKD","LU0109392836.USD","LU0061475181.USD","LU0070217475.USD","LU2089985449.USD","ESUM","NVD","LU1670756490.USD","LU1244550221.USD","LU2360106780.USD","LU2463028550.USD","LU2092937148.SGD","LU2242650005.HKD","LU0965509283.SGD","LU0444973449.USD","LU0265550359.USD","LU2265009873.SGD","LU2237443465.HKD","LU2417539215.USD","LU0476273544.USD","SG9999014880.SGD","LU2491050071.SGD","LU0868494708.USD","LU2271345857.HKD","SMH","LU2249611893.SGD","HK0000320264.USD","LU0786609619.USD","LU1814569148.SGD","LU2473716301.USD","LU1267930730.SGD","LU2430703095.HKD","IE000ITXATA3.USD","IE00BQXX3C00.GBP","LU0143551892.USD","LU2023250504.SGD","LU1699723380.USD","LU0154236417.USD","LU2168564149.EUR","BK4612","LU0345770308.USD","LU2083900584.USD","LU0861579265.USD","ARTY","LU0069063385.USD","LU0943347566.SGD","LU0029864427.USD","LU0882574139.USD","BK4529","DIPS","TEK","LU0965508806.USD","LU2242649171.HKD","LU2505996509.AUD","LU0158827781.USD","LU1633808545.USD","LU0210536198.USD","LU1066051225.USD","SG9999014906.USD","IE00B19Z8W00.USD","LU2237957811.SGD","IE00B7KXQ091.USD","SG9999014567.USD","LU0211327993.USD","HK0000304805.HKD","IETC","BK4527","LU0640476718.USD","LU1861127337.USD","LU0081259029.USD","SG9999014559.SGD","LU0345768153.USD","LU0174119429.USD","LU1037948897.HKD","BK4550","IE0004445239.USD","IE00BWXC8680.SGD","LU2236285917.USD","LU0965509101.SGD","LU2413666426.HKD","LU2491050154.USD","BK0077","LU2896262040.SGD","SG9999004303.SGD","HK0000532082.HKD","LU2244417387.USD","LU0225283273.USD","LU1791710400.SGD","LU1852331112.SGD","LU0057025933.USD","LU1804176565.USD","LU1400636657.SGD","IE0009356076.USD","LU2756315664.SGD","LU0238689110.USD","IE00B4JS1V06.HKD","SG9999018857.SGD","LU0289739343.SGD","IXN","LU1674673691.USD","IE0004091025.USD","HK0000306685.HKD","SGXZ99366536.SGD","LU2237443382.USD","JGRO","BK4534","LU1815333072.USD","LU1551013425.SGD","LU2430703251.USD","LU1084165304.USD","LU1366333091.USD","HK0000914660.USD","VT","LU2023251221.USD","LU0868494617.USD","LU2433249047.HKD","LU1323610961.USD","LU1935043536.SGD","BK4598","LU0234570918.USD","LU1935042215.USD","LU1496350502.SGD","LU0210528500.USD","LU0138981039.USD","LU0096364046.USD","LU2357125470.USD","IE0009G5SDU7.USD","LU0256863902.USD","NVDB","LU1116320901.HKD","SGXZ51526630.SGD","AGOX","IE00BQXX3F31.USD","LU0310800379.SGD","IE00BD6J9T35.USD","LU2264538146.SGD","LU2028103732.USD","LU0823414478.USD","LU1244550494.USD","SMHX","FAI","LU1267930573.SGD","LU2413666699.HKD","LU0820562030.AUD","TTEQ","LU0390134368.USD","SG9999018865.SGD","LU2237443622.USD","LU2487616109.SGD","LU2065171311.SGD","LU1242518931.SGD","002317","CHAT","LU1861220033.SGD","LU1992135399.USD","2NVD.UK","LU0348723411.USD","BK4605","LU2087625088.SGD","LU0320765059.SGD","IE000W1ABFV2.USD","LU0203201768.USD","LU0308772762.SGD","LU1983260115.SGD","LU0215105999.USD","IE00BJJMRY28.SGD","SG9999002232.USD","LU1778281490.HKD","SGXZ81514606.USD","LU2602419157.SGD","SOXY","BK4503","LU0689472784.USD","LU3102509885.SGD","SG9999017495.SGD","LU0323239441.USD","SG9999001424.SGD","SGXZ23171101.USD","AIFD","LU0175139822.USD","IE00B5949003.HKD","IE00BDRTCR15.USD","LU0708995401.HKD","LU1429558221.USD","LU1035773651.USD","IE0004086264.USD","IE00BFSS8Q28.SGD","LU1127390331.HKD","LU2452424414.USD","LU2237438978.USD","LU2361045086.USD","LU1066053197.SGD","LU0210533765.USD","LU2381873111.SGD","LU0203202063.USD","LU2322448957.HKD","LU1934455277.USD","BK0188","LU2462591277.SGD","IE00B1BXHZ80.USD","NVDS.UK","IE0001KFT4U8.USD","LU0965509010.AUD","LU2326559502.SGD","LU2860962120.EUR","LU2746668461.USD","LU2637965513.SGD","LU0719512351.SGD","LU1989764748.USD","CNEQ","LU0080751232.USD","LU1116320737.USD","LU2213496289.HKD","SG9999014575.USD","LU2168564495.EUR","LU0106261372.USD","LU0985320562.USD","IE000YTNTUN2.SGD","LU2505996681.GBP","IE00BZ1G4Q59.USD","LU0107464264.USD","LU0964807845.USD","LU2237957902.USD","LU0128525929.USD","IE00B3SWFQ91.USD","LU2097344357.USD","NVDL","LU2954938101.SGD","BK4567","SG9999002224.SGD","IE00BKDWB100.SGD","BK4581","LU2125909759.SGD","IE00BYXW3230.USD","LU0097036916.USD","LU0323240290.USD","IE00BJJMRX11.SGD","LU0957808578.USD","3NVD.UK","LU0345769128.USD","SG9999015986.USD","LU2290526834.HKD","ABFL","FDTX","LU0354030438.USD","NVDU","LU0289960550.SGD","BK4579","IE00B1XK9C88.USD","LU1064131342.USD","LU0889565833.HKD","NVDQ","LU0094547139.USD","IE00B19Z8X17.USD","NVD2.UK","LU2462157665.USD","IE0003U64NQ7.SGD","LU1145028129.USD","IE00BKVL7J92.USD","LU1066051811.HKD","LU1917777945.USD","LU0823421416.USD","LU0823434740.USD","LU2592432038.USD","SHOC","NVIW.SI","LU0096362180.USD","LU1989772840.SGD","LU2361044865.SGD","LU0472753341.HKD","TRFK","LU2286300806.USD","LU0077335932.USD","NVDD","LU1861215975.USD","LU0056508442.USD","LU0124676726.USD","LU1316542783.SGD","LU0949170772.SGD","LU2125909593.SGD","LU2065169927.USD","LU0787776722.HKD","LU1496350171.SGD","IE00BMPRXR70.SGD","LU2125154935.USD","LU2471134952.CNY","LU2047632596.USD","SG9999014898.SGD","LU2458330243.SGD","NVDG","LU1202635105.USD","IE00BN29S564.USD","NVDY","IE00BKPKM429.USD","SG9999015952.SGD","NVDS","LU1548497426.USD","LU0444971666.USD","LU0957791311.USD","IE00BK4W5M84.HKD","LFGY","LU1815336760.USD","LU2089284900.SGD","LU0274383776.USD","HK0000306701.USD","SNPE","LU0082616367.USD","LU2931357623.SGD","LU1868836757.USD","LU0170899867.USD","BK4588","LU0061474705.USD","LU0354030511.USD","LU1623119135.USD","LU1366192091.USD","LU0820561818.USD","AIPI","LU0823434583.USD","LU2054465674.USD","LU0127658192.USD","SPTE","BK4585","BK0239","LU2168563687.JPY","LU0267386448.USD","LU1868837136.USD","LU0234572021.USD","BK4543","LU0494093205.USD","LU2552382215.SGD","LU0511384066.AUD","NVDO","LU1821325948.USD","LU2272731600.USD","LU0724617625.USD","LU2168564065.EUR","LU2471134523.USD","IE000KEQY171.SGD","HK0000819398.USD","IE0034235295.USD","LU1988902786.USD","LU1951200564.SGD","LU2361044949.HKD","CLSE","LU0316494557.USD","METV","LU1989772923.USD","LU0345770993.USD","LU1923623000.USD","LU1718418525.SGD","LU1400636491.USD","SG9999014542.SGD","LU2125909916.SGD","LU2148611432.USD","IE00B775H168.HKD","NVYY","LU2250418816.HKD","IE00BMPRXN33.USD","LU1839511570.USD","LU1435385759.SGD","LU2168564222.USD","BK4533","LU2063271972.USD","LU2065170008.USD","LU1791710582.SGD","LU1935042991.SGD","LU2279689827.SGD","LU2756315318.SGD","LU0823414551.USD","LU1935042488.USD","ANV","LU2237443978.SGD","IE00BDCRKT87.USD","SNVD.UK","LU0708994859.HKD","LU0823421333.USD","VGT","ILDR","LU0738911758.USD","LU1974910355.USD","LU0553294199.USD","FTEC","LU1923622291.USD","LU2211815571.USD","LU1721428933.USD","IE00BJTD4N35.SGD","LU1066051498.USD","IE0005OL40V9.USD","NVII","SOXQ","LU2458330169.SGD","NVDW","LU2125154778.USD","LU1935043023.USD","LU2247934214.USD","HK0000320223.HKD","LU2100268510.USD","LU1400636574.HKD","LU1645745479.HKD","LU1720051108.HKD","LU1069344957.HKD","HK0000914686.HKD","HK0000304797.USD","LU1629891620.HKD","LU2087621335.USD","LU2750360641.GBP","LU0545039389.USD","LU0109391861.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652526119","title":"众生药业:先强药业致力于以优质的CDMO服务和核心技术产品成为特色原料药的价值创造者","url":"https://stock-news.laohu8.com/highlight/detail?id=2652526119","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652526119?lang=zh_cn&edition=full","pubTime":"2026-07-20 11:36","pubTimestamp":1784518583,"startTime":"0","endTime":"0","summary":"证券之星消息,众生药业(002317)07月20日在投资者关系平台上答复投资者关心的问题。投资者提问:你好,请问公司有开展CDMO业务吗?,子公司是不是有这个业务众生药业回复:您好!公司全资子公司先强药业致力于以优质的CDMO服务和核心技术产品成为特色原料药的价值创造者,其充分利用原料药CDMO的技术和制造能力,接受定制化的订单和生产自研产品,满足药品制剂企业的关联审评需求。谢谢!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:沈彬","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072000012621.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002317","BK0239","BK0188","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652406509","title":"7月17日众生药业跌5.44%,红土创新医疗保健股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652406509","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652406509?lang=zh_cn&edition=full","pubTime":"2026-07-17 16:42","pubTimestamp":1784277754,"startTime":"0","endTime":"0","summary":"证券之星消息,7月17日众生药业跌5.44%,收盘报28.33元,换手率10.17%,成交量77.47万手,成交额22.68亿元。根据2026基金半年报公募基金重仓股数据,重仓该股的公募基金共1家,其中持有数量最多的公募基金为红土创新基金的红土创新医疗保健股票A。红土创新医疗保健股票A的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700030397.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002317","BK0239","BK0188","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651547440","title":"众生药业(002317)披露2024年员工持股计划锁定期届满暨解锁条件成就公告,7月16日股价下跌10.0%","url":"https://stock-news.laohu8.com/highlight/detail?id=2651547440","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651547440?lang=zh_cn&edition=full","pubTime":"2026-07-16 22:02","pubTimestamp":1784210541,"startTime":"0","endTime":"0","summary":"截至2026年7月16日收盘,众生药业报收于29.96元,较前一交易日下跌10.0%,最新总市值为254.64亿元。公告显示,公司于2026年7月16日召开第九届董事会第四次会议,审议通过关于2024年员工持股计划首次授予部分第二个锁定期及预留授予部分第一个锁定期解锁条件成就的议案。本次锁定期届满,公司层面业绩考核达标,创新药研发进度达到目标值,营业收入完成触发值以上,公司层面解锁比例为100%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071600039924.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0239","BK0188","002317"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651410221","title":"7月16日众生药业(002317)龙虎榜数据:机构净卖出5211.89万元,北向资金净买入5098.97万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2651410221","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651410221?lang=zh_cn&edition=full","pubTime":"2026-07-16 17:22","pubTimestamp":1784193770,"startTime":"0","endTime":"0","summary":"证券之星消息,沪深交易所2026年7月16日公布的交易公开信息显示,众生药业因日跌幅偏离值达到7%的前5只证券登上龙虎榜。此次是近5个交易日内第2次上榜。截至2026年7月16日收盘,众生药业报收于29.96元,下跌10.0%,换手率12.79%,成交量97.39万手,成交额30.4亿元。从龙虎榜公布的当日买卖数据来看,机构合计净卖出5211.89万元,北向资金合计净买入5098.97万元。深股通专用、沪股通专用为北向资金的交易席位。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071600028169.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002317","BK0239","BK0188","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651041207","title":"7月16日众生药业跌10.00%,红土创新医疗保健股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2651041207","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651041207?lang=zh_cn&edition=full","pubTime":"2026-07-16 16:27","pubTimestamp":1784190477,"startTime":"0","endTime":"0","summary":"证券之星消息,7月16日众生药业跌10.00%,收盘报29.96元,换手率12.79%,成交量97.39万手,成交额30.4亿元。根据2026基金半年报公募基金重仓股数据,重仓该股的公募基金共1家,其中持有数量最多的公募基金为红土创新基金的红土创新医疗保健股票A。红土创新医疗保健股票A的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071600026415.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0077","002317"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651460830","title":"股市必读:众生药业(002317)7月15日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2651460830","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651460830?lang=zh_cn&edition=full","pubTime":"2026-07-16 01:18","pubTimestamp":1784135891,"startTime":"0","endTime":"0","summary":"截至2026年7月15日收盘,众生药业报收于33.29元,上涨6.87%,换手率12.74%,成交量97.01万手,成交额32.03亿元。公司控股子公司众生睿创与齐鲁制药签署《许可协议》,众生睿创授权齐鲁制药在中国地区内对RAY1225注射液进行生产与商业化销售,是公司推动创新药平台建设与后续新药上市商业化的重要举措。当日关注点交易信息汇总:7月15日主力资金净流出1574.1万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071600001640.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0077","BK0188","002317"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651879434","title":"半年BD狂飙千亿、龙头预增13倍!创新药涨停潮再起","url":"https://stock-news.laohu8.com/highlight/detail?id=2651879434","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651879434?lang=zh_cn&edition=full","pubTime":"2026-07-15 13:50","pubTimestamp":1784094601,"startTime":"0","endTime":"0","summary":"政策密集加码","market":"us","thumbnail":"https://img3.gelonghui.com/9d73a-d7eab21c-e179-4850-9c4c-edf64e1fd8eb.jpg?guru_height=716&guru_width=1280&guru_size=127989","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/9d73a-d7eab21c-e179-4850-9c4c-edf64e1fd8eb.jpg?guru_height=716&guru_width=1280&guru_size=127989"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/5584162","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK0012","BK0060","BK0216","MEDX","BD","002317","BK0239","688192","BK0028","BK0077","BK1574","002940","000566","159992","BK0070","600664","300149","06978","BK0188","IBBQ","BK0146","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1786789909551,"stockEarnings":[{"period":"1week","weight":-0.0395},{"period":"1month","weight":-0.1754},{"period":"3month","weight":0.2904},{"period":"6month","weight":0.4613},{"period":"1year","weight":0.3345},{"period":"ytd","weight":0.459}],"compareEarnings":[{"period":"1week","weight":-0.0033},{"period":"1month","weight":-0.0072},{"period":"3month","weight":-0.0503},{"period":"6month","weight":-0.0379},{"period":"1year","weight":0.0711},{"period":"ytd","weight":-0.0105}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"广东众生药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"111004人(较上一季度减少2.61%)","perCapita":"6861股","listingDate":"2009-12-11","address":"广东省东莞市石龙镇西湖工业区信息产业园","registeredCapital":"84993万元","survey":" 广东众生药业股份有限公司的主营业务是药品研发、生产和销售。公司的主要产品是昂拉地韦片、来瑞特韦片、复方血栓通系列产品、脑栓通胶囊、复方丹参片、众生丸系列产品、清热祛湿颗粒、羧甲司坦口服溶液(片)、盐酸氨溴索口服溶液、头孢克肟分散片、头孢拉定胶囊、异烟肼片、吡嗪酰胺片、盐酸乙胺丁醇片、利福平胶囊、利巴韦林片、硫糖铝口服混悬液、瑞巴派特片、奥美拉唑肠溶胶囊、盐酸氮䓬斯汀滴眼液、普拉洛芬滴眼液、地夸磷索钠滴眼液、环孢素滴眼液(III)、氯雷他定片、富马酸氯马斯汀口服溶液。","listedPrice":55},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"众生药业(002317)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供众生药业(002317)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"众生药业,002317,众生药业股票,众生药业股票老虎,众生药业股票老虎国际,众生药业行情,众生药业股票行情,众生药业股价,众生药业股市,众生药业股票价格,众生药业股票交易,众生药业股票购买,众生药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"众生药业(002317)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供众生药业(002317)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}